News

Retrotope’s RT001 Reduced Cognitive Defects in Mice with Huntington’s Disease, Study Shows

Retrotope’s investigative therapy RT001 reduced cognition deficits in  mice with Huntington’s disease, and was found to lower the amount of oxidative damage in their brains. The study, “Deuterium‐reinforced linoleic acid lowers lipid peroxidation and mitigates cognitive impairment in the Q140 knock in mouse model of Huntington’s disease,” was published in…

Skyhawk, Celgene Partner to Develop Small Molecule Treatments for Huntington’s, Other Neurological Diseases

Skyhawk Therapeutics and Celgene have entered into a five-year global partnership to use Skyhawk’s STAR* technology platform to discover, advance, and commercialize new small-molecule therapies to treat patients with neurological diseases, including Huntington’s disease. The STAR* approach, which stands for “small-molecule therapies for alternative splicing in RNA,” aims to correct the…

Experts Seeking Tools to Assess Effectiveness of Targeted Huntington’s Therapies

Improved measures to accurately determine the effectiveness of treatments targeting Huntington’s disease are necessary, according to clinical neurologists and Huntington’s specialists. The editorial, “Improved metrics for Huntington’s disease trials,” reflects on recent advances made for the development of targeted agents that can effectively change the course of Huntington’s disease.

Novel Spotlights Daily Struggles of Patients and Families

“You Me Everything,” a novel about a single mom whose mother is diagnosed with Huntington’s disease, is helping to raise awareness of the condition. The story is also drawing attention to the struggles of patients and their loved ones. In writing the novel, British author Catherine Isaac sought…